Tilak Announces CE Marking for Odysight, Its First Mobile Medical Game in Ophthalmology

Launching of the Beta-testing phase in France and in the United
Kingdom

PARIS–(BUSINESS WIRE)–Tilak, a company from the iBionext network developing mobile medical
applications for the management of chronic diseases, announced that
Odysight, its first mobile medical game dedicated to the monitoring of
patients with chronic eye diseases, has achieved CE marking. CE marking
triggers the Beta testing phase of Odysight with ophthalmologists in
France, followed by the United Kingdom.

Odysight has innovative and distinctive features, unique in the world of
mobile therapeutic gaming:

  • It was designed in-house by doctors and realized by video game
    professionals;
  • It is a puzzle game for smartphone and tablet;
  • It brings together all the elements of a modern mobile video game: an
    innovative artistic direction, simple game mechanics, a level of
    difficulty adapted to the patient
  • It monitors the evolution of visual parameters (near visual acuity,
    contrast sensitivity, presence and evolution of scotomas or
    metamorphosis) and triggers regular medical tests for the follow-up of
    patients with chronic eye diseases.

Odysight is available on the App Store and Google Play, only via medical
prescription. The ophthalmologist can follow in real time or during the
consultation the evolution of the patient’s visual parameters via an
online dashboard. He is alerted if a change occurs.

« Obtaining the CE mark for Odysight is a key step in the company’s
development. The mobile video game, a real medical monitoring tool, has
become an integral part of the care pathway for patients, especially
those suffering from chronic diseases which are growing rapidly in
western countries »
said Edouard Gasser, CEO of Tilak.

About Tilak
Co-founded with iBionext in May 2016, Tilak is a
company of the iBionext ecosystem. It specializes in digital healthcare
and is dedicated to the development of medically-prescribed disruptive
mobile games for the monitoring and follow-up of patients suffering from
chronic diseases. The company’s first game targets ophthalmology,
particularly chronic diseases of the macula, which are the leading
causes of treatable blindnesss for the elderly in developed countries.
Tilak’s objective is to improve the management of these diseases and
optimize the healthcare process.
For more information : http://www.tilakhealthcare.com/

About iBionext
Created in September 2015, iBionext is a
management company and a start-up studio dedicated to the development of
innovative start-ups in healthcare. This initiative, launched by Bernard
Gilly in 2012, aims to transform technological breakthrough ideas into
leading innovative start-ups in the fields of HealthTech and related
industrial applications. All these companies are grouped on a single
site named the “Passage de l’Innovation” in Paris, France.
Since
2012, eight companies were created within the iBionext ecosystem –
Pixium Vision (Euronext: PIX), GenSight Biologics (Euronext: SIGHT),
Gecko Biomedical, ChronoCam, ChronoLife, BrainEver, Tilak Healthcare and
Brainiac. iBionext and its companies have raised over 360 million euros
in capital (of which € 90 million was raised by iBionext Growth Fund).
Seven clinical trials are currently underway worldwide and 190
experienced professionals have joined these companies.
iBionext
Growth Fund was created in 2016 to finance the growth of new companies
selected within the iBionext network.
For more information : http://ibionext.com/

Contacts

Tilak
Edouard Gasser – +33 (0) 7 62 27 18 42
egasser@tilakhealthcare.com
or
Media
NewCap
Annie-Florence
Loyer
+33 (0)1 44 71 00 12 / +33 (0)6 88 20 35 59
afloyer@newcap.fr
or
Léa
Jacquin, +33 (0)1 44 71 20 41
ljacquin@newcap.fr